Avacta Group (LON:AVCT) Sets New 12-Month Low – Time to Sell?

Avacta Group Plc (LON:AVCTGet Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as GBX 28.83 ($0.37) and last traded at GBX 35.50 ($0.45), with a volume of 4674920 shares traded. The stock had previously closed at GBX 33.44 ($0.43).

Avacta Group Price Performance

The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53. The company has a fifty day simple moving average of GBX 39.93 and a two-hundred day simple moving average of GBX 46.92. The company has a market cap of £136.77 million, a price-to-earnings ratio of -4.63 and a beta of 1.12.

Avacta Group Company Profile

(Get Free Report)

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

Further Reading

Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.